On the other hand, in the phase II CARMEN-LC06 trial, the activity of this compound for previously treated NSCLC patients who are negative/moderate CEACAM5 expressors and with high levels of circulating-carcinoembryonic-antigen (CEA) is under investigation [50]. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.